AnaptysBio, Inc.

Report azionario NasdaqGS:ANAB

Capitalizzazione di mercato: US$1.5b

AnaptysBio Gestione

Criteri Gestione verificati 4/4

AnaptysBio Il CEO è Dan Faga, nominato in Mar2022, e ha un mandato di 4.25 anni. la retribuzione annua totale è $ 6.13M, composta da 11.5% di stipendio e 88.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.71% delle azioni della società, per un valore di $ 25.51M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.4 anni e 4 anni.

Informazioni chiave

Dan Faga

Amministratore delegato

US$6.1m

Compenso totale

Percentuale dello stipendio del CEO11.51%
Mandato del CEO4.3yrs
Proprietà del CEO1.7%
Durata media del management2.4yrs
Durata media del Consiglio di amministrazione4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Seeking Alpha • Apr 21

AnaptysBio: 'Hold' As Spin-Off Shifts Pipeline To First Tracks Biotherapeutics

Summary AnaptysBio has spun off its biopharma pipeline into First Tracks Biotherapeutics, shifting to a royalty-focused, virtual business model. I maintain a "Hold" rating on both ANAB and TRAX, given the need for further clinical data and clarity on pipeline advancement and partnerships. ANAB retains royalty streams from JEMPERLI [GlaxoSmithKline] and imsidolimab (Vanda Pharmaceuticals), with JEMPERLI sales growing and a PDUFA date for imsidolimab set for Dec 2026. TRAX's value hinges on upcoming ANB033 data in celiac disease [Q4 2026] and EoE [mid-2027], and potential strategic financing for rosnilimab in RA Q2 2026. Read the full article on Seeking Alpha
Articolo di analisi • Jul 16

AnaptysBio, Inc.'s (NASDAQ:ANAB) Share Price Not Quite Adding Up

With a median price-to-sales (or "P/S") ratio of close to 8.6x in the Biotechs industry in the United States, you could...
Articolo di analisi • Jun 11

Shareholders May Be More Conservative With AnaptysBio, Inc.'s (NASDAQ:ANAB) CEO Compensation For Now

Key Insights AnaptysBio to hold its Annual General Meeting on 17th of June Salary of US$685.4k is part of CEO Dan...
Articolo di analisi • May 08

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

It's been a mediocre week for AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders, with the stock dropping 11% to US$19.68 in...
Articolo di analisi • May 07

Is AnaptysBio (NASDAQ:ANAB) Using Debt Sensibly?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Articolo di analisi • Apr 03

AnaptysBio, Inc.'s (NASDAQ:ANAB) Price Is Right But Growth Is Lacking After Shares Rocket 30%

Despite an already strong run, AnaptysBio, Inc. ( NASDAQ:ANAB ) shares have been powering on, with a gain of 30% in the...
Seeking Alpha • Mar 06

AnaptysBio: A Shadow Of Its Former Self

Summary ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns. The recent deal for Imsidolimab reflects low confidence in the drug's market potential, despite positive phase 3 results. Rosnilimab showed promising trial results but failed to differentiate significantly from existing treatments, raising doubts about its competitive edge. Financials show a cash runway of 6-7 quarters, but high expenses and limited revenue sources maintain the risk profile. Read the full article on Seeking Alpha
Articolo di analisi • Feb 14

AnaptysBio, Inc. (NASDAQ:ANAB) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected

AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders would be excited to see that the share price has had a great month...
Seeking Alpha • Dec 18

AnaptysBio: Doubts About Cash And Upcoming Rheumatoid Arthritis Readout

Summary The failure of ANB032 in Phase 2B for atopic dermatitis has shifted focus to rosnilimab, which faces significant competition and uncertain prospects. Rosnilimab's upcoming Phase 2B results for rheumatoid arthritis in February 2025 are crucial, but Eli Lilly's discontinuation of a similar drug raises concerns. If rosnilimab fails to deliver, the company's mid-stage pipeline may not hold much promise any more. Anaptys estimates that it will have about $415 million in the bank at the end of the year. Read the full article on Seeking Alpha
Seeking Alpha • Nov 21

AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching

Summary AnaptysBio has been able to use its technology to develop 2 compelling lead drug candidates. Their pipeline has 2 key readouts in December 2024 and February 2025 worth monitoring. The near-term catalysts include a Phase 2b trial for the drug candidates rosnilimab and ANB032, which are crucial for re-evaluating AnaptysBio’s stock value. Despite this promising pipeline and experienced leadership team, the competitive landscape within immunology and potential clinical trial failures present substantial risks to AnaptysBio’s progress. Read the full article on Seeking Alpha
Articolo di analisi • Nov 07

AnaptysBio, Inc. (NASDAQ:ANAB) May Have Run Too Fast Too Soon With Recent 33% Price Plummet

The AnaptysBio, Inc. ( NASDAQ:ANAB ) share price has fared very poorly over the last month, falling by a substantial...
Seeking Alpha • Nov 01

AnaptysBio: Too Risky, Especially After GSK Drops Its Related Programs

Summary ANAB has a past history of successes. There are two molecules in phase 2, but with no patient data. The GSK news has hurt the stock. Read the full article on Seeking Alpha
Seeking Alpha • Aug 15

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

Summary AnaptysBio, Inc. 14-week results from the phase 2b study, using ANB032 for the treatment of patients with moderate-to-severe Atopic Dermatitis, expected in December 2024. The global Atopic dermatitis market is expected to reach $19.49 billion by 2034. Top-line 12-week data from the phase 2b study, using rosnilimab for the treatment of patients with moderate-to-severe rheumatoid arthritis, expected in Q1 of 2025. The company raised $100 million in gross proceeds through a registered direct stock offering, substantially increasing its cash runway. Read the full article on Seeking Alpha
Seeking Alpha • Jul 08

AnaptysBio: Interesting Prospects, But Wait For The Dip (Rating Downgrade)

Summary AnaptysBio, Inc. receives a "Hold" rating for its U.S.-listed shares. It shows a 16.42% increase in stock market value since the last "Buy" rating. AnaptysBio's immunotherapy portfolio includes promising projects such as Rosnilimab, ANB032, ANB033, Imsidolimab, and Etokimab, with positive progress and the potential to develop into a profitable source of income. Financial partnership with GSK plc also bodes favorably with AnaptysBio's hopes for additional growth, despite a net loss in the first quarter of 2024. As in the past, the apparent continuation of Fed tightening for a longer period than market participants expect will create downward pressure. This analysis concludes that there are good reasons to believe that another sharp price drop is on the horizon. Read the full article on Seeking Alpha
Articolo di analisi • May 22

News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders will have a reason to smile today, with the analysts making substantial...
Articolo di analisi • May 12

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

There's been a notable change in appetite for AnaptysBio, Inc. ( NASDAQ:ANAB ) shares in the week since its...
Articolo di analisi • Feb 22

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Articolo di analisi • Oct 10

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Dan Faga rispetto agli utili di AnaptysBio?
DataCompenso totaleStipendioUtili della società
Mar 31 2026n/an/a

-US$27m

Dec 31 2025US$6mUS$706k

-US$13m

Sep 30 2025n/an/a

-US$85m

Jun 30 2025n/an/a

-US$133m

Mar 31 2025n/an/a

-US$141m

Dec 31 2024US$14mUS$685k

-US$145m

Sep 30 2024n/an/a

-US$166m

Jun 30 2024n/an/a

-US$170m

Mar 31 2024n/an/a

-US$163m

Dec 31 2023US$7mUS$641k

-US$164m

Sep 30 2023n/an/a

-US$148m

Jun 30 2023n/an/a

-US$144m

Mar 31 2023n/an/a

-US$137m

Dec 31 2022US$25mUS$474k

-US$129m

Sep 30 2022n/an/a

-US$135m

Jun 30 2022n/an/a

-US$108m

Mar 31 2022n/an/a

-US$76m

Dec 31 2021US$310kn/a

-US$58m

Compensazione vs Mercato: La retribuzione totale di Dan ($USD 6.13M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 5.30M ).

Compensazione vs guadagni: La retribuzione di Dan è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Dan Faga (46 yo)

4.3yrs
Mandato
US$6,133,943
Compensazione

Mr. Daniel R. Faga, also known as Dan, is President, chief executive officer and Director of AnaptysBio, Inc. from August 2023. He was Interim President & CEO and Director of AnaptysBio, Inc. from March 21...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Daniel Faga
President4.3yrsUS$6.13m1.71%
$ 25.5m
Christopher Murphy
Chief Financial Officerless than a yearNessun datoNessun dato
Beth Mueller
Senior Vice President of Human Resources6.7yrsNessun datoNessun dato
Martin Dahl
Senior Vice President of Research4.4yrsNessun datoNessun dato
Benjamin Stone
Chief Business Officer2.4yrsNessun datoNessun dato
Monique Da Silva
Senior Vice President of Corporate Affairs2.4yrsNessun datoNessun dato
Priya Raina
Senior Vice President of Clinical Operations2.4yrsNessun datoNessun dato
Cailin Sibley
Senior Vice President of Translational Medicineno dataNessun datoNessun dato
John Kwon
Vice President of GI Clinical Developmentno dataNessun datoNessun dato
2.4yrs
Durata media
42yo
Età media

Gestione esperta: Il team dirigenziale di ANAB è considerato esperto (durata media dell'incarico 2.4 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Daniel Faga
President4.6yrsUS$6.13m1.71%
$ 25.5m
John Orwin
Independent Chairman of the Board2.8yrsUS$370.23k0.037%
$ 547.8k
Hollings Renton
Lead Independent Director11yrsUS$426.69k0.017%
$ 255.0k
John Schmid
Independent Director11yrsUS$336.98k0.11%
$ 1.6m
Owen Hughes
Directorless than a yearNessun datoNessun dato
Susannah Gray
Independent Directorless than a yearNessun datoNessun dato
Oleg Nodelman
Independent Director5.2yrsNessun datoNessun dato
Dolca Thomas
Member of Scientific Advisory Board3.4yrsNessun datoNessun dato
Luisa Salter-Cid
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Christopher Hunter
Member of Scientific Advisory Boardno dataNessun datoNessun dato
John Monroe
Member of Scientific Advisory Boardno dataNessun datoNessun dato
4.0yrs
Durata media
61yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ANAB sono considerati esperti (durata media dell'incarico 4 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/06/09 12:11
Prezzo dell'azione a fine giornata2026/06/09 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

AnaptysBio, Inc. è coperta da 18 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Neena Bitritto-GargBaird
Etzer DaroutBarclays
Michael KingCitizens JMP Securities, LLC